natgillin/translations-raw huggingface dataset:
• Acetylsalicylic acid (if you are taking more than 3 g each day) (medicine to relieve pain and inflammation). 
• acetilsalicilno kislino (če jo jemljete več kot 3 g vsak dan) (zdravilo za lajšanje bolečin in ublažitev vnetja).
It is important that you are aware of what these side effects may be. 
Pomembno je, da veste, kakšni so lahko neželeni učinki.
There is currently no data on the effect of candesartan on the progression to diabetic nephropathy. 
Trenutno ni podatkov o učinku kandesartana na napredovanje diabetične nefropatije.
Whilst there is no controlled epidemiological data on the risk with AIIRAs, similar risks may exist for this class of drugs. 
Medtem, ko ni na voljo nadzorovanih epidemioloških podatkov o tveganju z uporabo AIIRA, lahko za to skupino zdravil obstaja podobno tveganje.
The presentation of results of a study in hypertension in the elderly was also harmonised. 
Usklajena je bila tudi predstavitev rezultatov študije hipertenzije pri starostnikih.
If this happens contact your doctor. 
Če se to zgodi, se posvetujte z zdravnikom.
There is no indication of serious or exaggerated first dose hypotension or rebound effect after cessation of treatment. 
Ni znakov, da bi se po prvem odmerku pojavila resna ali čezmerna hipotenzija, ali da bi se po prenehanju zdravljenja pojavil povratni učinek.
Your doctor may occasionally do blood tests to check whether Atacand has had any effect on your blood (agranulocytosis). 
Zdravnik vam bo morda občasno opravil preiskavo krvi, da bo preveril, ali vam zdravilo Atacand vpliva na kri (agranulocitoza).
• severe itching of the skin (with raised lumps) 
• hudo srbenje kože (z dvignjenimi izboklinami).
• if you are more than 3 months pregnant (it is also better to avoid Atacand in early pregnancysee pregnancy section). 
• če ste noseči več kot 3 mesece (dobro je, da se zdravilu Atacand izognete tudi v zgodnji nosečnosti - glete poglavje o nosečnosti).
In controlled clinical studies adverse reactions were mild and transient. 
V kontroliranih kliničnih študijah so bili neželeni učinki blagi in prehodni.
Atacand and associated names (see Annex I) 2 mg tablets Atacand and associated names (see Annex I) 4 mg tablets Atacand and associated names (see Annex I) 8 mg tablets Atacand and associated names (see Annex I) 16 mg tablets Atacand and associated names (see Annex I) 32 mg tablets 
Atacand in povezana imena (glejte Dodatek I) 2 mg tablete Atacand in povezana imena (glejte Dodatek I) 4 mg tablete Atacand in povezana imena (glejte Dodatek I) 8 mg tablete Atacand in povezana imena (glejte Dodatek I) 16 mg tablete Atacand in povezana imena (glejte Dodatek I) 32 mg tablete
• Respiratory infection. 
• Okužba dihal.
After 6 months of treatment 63% of the patients still taking candesartan cilexetil (89%) were at the target dose of 32 mg. 
Po 6 mesecih zdravljenja je 63 % bolnikov, ki so še vedno jemali cileksetilkandesartanat (89 %), uporabljalo ciljni odmerek 32 mg.
The relative bioavailability of the tablet formulation compared with the same oral solution is approximately 34% with very little variability. 
Relativna biološka uporabnost tablet v primerjavi z isto peroralno raztopino je približno 34 % in kaže zelo majhno variabilnost.
No studies on the effects of candesartan on the ability to drive and use machines have been performed. 
Študije o vplivih kandesartana na sposobnost vožnje in upravljanja s stroji niso bile izvedene.
These changes were considered to be caused by the pharmacological action of candesartan. 
Te spremembe so ocenili za posledice farmakološkega delovanja kandesartana.
Atacand may cause a reduction in number of white blood cells. 
Zdravilo Atacand lahko povzroči zmanjšanje števila belih krvnih celic.
If you stop taking Atacand, your blood pressure may increase again. 
Če prenehate jemati zdravilo Atacand, se vam krvni tlak lahko znova zviša.
The antihypertensive action is due to decreased systemic peripheral resistance, without reflex increase in heart rate. 
Antihipertenzivno delovanje je posledica zmanjšane sistemske periferne upornosti, brez refleksnega povečanja srčne frekvence.
Other possible side effects include: 
Drugi možni neželeni učinki so:
A similar effect may occur with AIIRAs. 
Podoben učinek se lahko pojavi pri AIIRA.
The frequencies used in the tables throughout section 4.8 are: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and very rare 
Pogostnosti, uporabljane v preglednicah v celotnem poglavju 4.8, so: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000) in zelo redki
• if you have a disease of the adrenal gland called Conn's syndrome (also called primary hyperaldosteronism). 
• če imate bolezen nadledvičnih žlez, ki se imenuje Connov sindrom (ali primarni hiperaldosteronizem).
• Do not use Atacand after the expiry date which is stated on the carton, blister pack or bottle. 
• Zdravila Atacand ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli, pretisnem omotu ali plastenki.
Atacand is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely. 
Zdravila Atacand ne priporočamo materam, ki dojijo in vaš zdravnik bo za vas lahko izbral drugo zdravljenje, če boste želeli dojiti, posebno, če je vaš otrok novorojenček ali se je rodil predčasno.
According to a meta-analysis, the average additional effect of a dose increase from 16 mg to 32 mg once daily was small. 
Po ugotovitvah metaanalize je bil povprečni dodatni učinek povečanja odmerka s 16 mg na 32 mg enkrat na dan majhen.
WHAT ATACAND IS AND WHAT IT IS USED FOR 
KAJ JE ZDRAVILO ATACAND IN ZA KAJ GA UPORABLJAMO
Clinical trials in heart failure did not include patients with serum creatinine > 265 mol/l (> 3 mg/dl). 
Klinična preskušanja pri srčnem popuščanju niso vključila bolnikov s kreatininom v serumu > 265 mol/l (> 3 mg/dl).
The mean peak serum concentration (Cmax) is reached 3-4 hours following tablet intake. 
Povprečna največja koncentracija v serumu (Cmax) je dosežena v 3 do 4 urah po zaužitju tablete.
• you must tell your doctor if you think you are (or might become) pregnant. 
• Zdravniku morate povedati, če mislite, da ste noseči (ali da bi lahko zanosili).
Atacand can affect the way some other medicines work and some medicines can have an effect on Atacand. 
Zdravilo Atacand lahko vpliva na delovanje nekaterih drugih zdravil in nekatera druga zdravila lahko vplivajo na njegovo delovanje.
No clinically significant pharmacokinetic interactions with these medicinal products have been identified. 
Niso ugotovili nobenih klinično pomembnih farmakokinetičnih medsebojnih delovanj s temi zdravili.
Patients who receive such combination therapy require careful and regular monitoring. 
Bolniki, ki so prejemali takšno kombinirano zdravljenje, zahtevajo natančno in redno spremljanje.
This section was shortened and harmonised taking into account the current scientific knowledge and in line with the discussions for other sections of the SPC. 
To poglavje je bilo skrajšano in usklajeno z upoštevanjem trenutnega znanstvenega znanja ter razprave v zvezi z drugimi poglavji povzetka glavnih značilnosti zdravila.
Some studies support the addition of a calcium channel blocker (CCB), as additional strategy, (Farsang et al 2001, Morgan and Anderson 2002 and Lindholm et al 2003). 
Določene študije zaradi dodatne sinergije podpirajo dodatek zaviralca kalcijevih kanalčkov (Farsang et al 2001, Morgan and Anderson 2002 in Lindholm et al 2003).
• treating high blood pressure (hypertension) in adult patients. 
• zdravljenje visokega krvnega tlaka (hipertenzije) pri odraslih bolnikih.
The safety and efficacy of Atacand in children aged between birth and 18 years have not been established in the treatment of hypertension and heart failure. 
Varnost in učinkovitost Atacanda pri otrocih (od rojstva do 18. let) za zdravljenje hipertenzije in srčnega popuščanja ni ugotovljena.
Frequency Undesirable Effect 
Pogostnost Neželeni učinek
The 32 mg dose is supported by study results in hypertensive patients and by a recently published dose-response analysis by Karlson et al 2009. 
Odmerek 32 mg podpirajo rezultati študije pri bolnikih s hipertenzijo in nedavno objavljene analize odvisnosti odmerka in odziva, ki so jo izvedli Karlson et al 2009.
• if you are vomiting, have recently had severe vomiting, or have diarrhoea. 
• če bruhate, ste pred kratkim hudo bruhali, ali imate drisko.
• if you have low blood pressure. 
• če imate nizek krvni tlak.
Based on in vitro data, no interaction would be expected to occur in vivo with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4. 
Na osnovi in vitro podatkov, ne pričakujemo, da bo in vivo prišlo do interakcij z zdravili, katerih metabolizem je odvisen od izoencimov citokroma P450 CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 ali CYP3A4.
- the Summary of Products Characteristic, labelling and package leaflet proposed by the Marketing Authorisation Holders have been assessed based on the documentation submitted and the scientific discussion within the Committee, 
- Povzetek glavnih značilnosti zdravil, označevanje in navodilo za uporabo, ki jih predlagal imetnik dovoljenja za promet, so bili ocenjeni na osnovi predložene dokumentacije in znanstvene razprave v Odboru.
The CHMP considered that the safety information in hypertension and chronic heart failure (CHF) should be presented separately. 
CHMP je menil, da je treba podatke o varnosti pri hipertenziji in kroničnem srčnem popuščanju predstaviti ločeno.
The symptomatic manifestations of overdose and recommendations on management if it occurs were included in this section. 
V to poglavje so bile vključene simptomatske manifestacije prekomernega odmerjanja in priporočila za ukrepanje, če do tega pride.
The hypertension indication was approved in all member states (MSs). 
Indikacija hipertenzije je bila odobrena v vseh državah članicah.
The recent ESH guidelines (Mancia et al 2007) and the Joint National Committee (JNC) VII guidelines (Chobanian et al 2003) for the treatment of hypertension state that the benefit may be substantial even when blood pressure reductions are small, and the initial blood pressure is below the traditional cut off defining hypertension. 
Nedavno objavljene smernice ESH (smernice Evropskega združenja za hipertenzijo) (Mancia et al 2007) in smernice JNC VII (smernice Ameriškega združenega nacionalnega odbora) (Chobanian et al 2003) za zdravljenje hipertenzije določajo, da je lahko koristni učinek bistven tudi, ko so znižanja krvnega tlaka majhna in je začetni krvni tlak pod običajno mejno vrednostjo, s katero je opredeljena hipertenzija.
Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. 
Epidemiološki podatki glede teratogenega tveganja po izpostavljenosti zaviralcem ACE med prvim trimesečjem niso dokončni: vendar manjšega povečanja tveganja ne moremo izključiti.
The antihypertensive effect of candesartan is less pronounced in black patients than in non-black patients. 
Antihipertenzivni učinek kandesartana je manj izražen pri bolnikih-črncih kot pri bolnikih-nečrncih.
In the PostMarketing sub-section, the frequency “Very Rare” was replaced with the frequency “not known” as, for post marketing experience the frequency could not be estimated in accordance with the guideline on the SPC (September 2009). 
V podpoglavju o ugotovitvah po pridobitvi dovoljenja za promet je bila pogostnost „zelo redko“ zamenjana s pogostnostjo „neznano“, za ugotovitve po pridobitvi dovoljenja za promet pogostnosti ni možno oceniti in le-ta ne more biti v skladu s priporočilom o povzetku glavnih značilnosti zdravila (september 2009).
CARTON FOR BLISTER / CARTON FOR BOTTLE / LABEL FOR BOTTLE 
ŠKATLA ZA PRETISNI OMOT / ŠKATLA ZA PLASTENKO / NALEPKA ZA PLASTENKO
• Back pain, pain in joints and muscles. 
• Bolečine v hrbtu, bolečine v sklepih in mišicah.
Moreover, there is no obvious biological reason for patients classified in NYHA class IV to respond differently to candesartan than other patients such as those classified to NYHA class III. 
Ravno tako ni jasnih bioloških razlogov, da bi se bolniki, razvrščeni v razred IV po NYHA, na kandesartan odzivali drugače kot drugi bolniki, npr. bolniki, razvrščeni v razred III po NYHA.
Addition of hydrochlorothiazide has been shown to have an additive antihypertensive effect with various doses of Atacand. 
Dokazano je, da ima dodatek hidroklorotiazida aditiven antihipertenziven učinek z različnimi odmerki Atacanda.
The corresponding changes in patients with severe renal impairment were approximately 50% and 110%, respectively. 
Pri bolnikih s hudo okvaro ledvic sta bili ti spremembi 50 % oz. 110 %.
However, the approved indication in one MS excluded patients falling in the New York Heart Association (NYHA) functional class IV. 
Vendar je odobrena indikacija v eni državi članici izključevala bolnike, ki spadajo v funkcijski razred IV po lestvici Newyorškega združenja za srce (NYHA).
In particular, the indications and their associated posology recommendations, the contraindications and special warnings and precautions for use were harmonised. 
Usklajene so bile zlasti indikacije, z njimi povezana priporočila za odmerjanje, kontraindikacije ter posebna opozorila in previdnostni ukrepi.
The major physiological effects of angiotensin II, such as vasoconstriction, aldosterone stimulation, regulation of salt and water homeostasis and stimulation of cell growth, are mediated via the type 1 (AT1) receptor. 
Glavni fiziološki učinki angiotenzina II, npr. vazokonstrikcija, stimulacija aldosterona, uravnavanje homeostaze soli in vode ter stimulacija celične rasti, potekajo prek receptorjev tipa 1 (AT1).
The possibility of similar effects cannot be excluded with AIIRAs. 
Pri AIIRA ni mogoče izključiti podobnih učinkov.
It also has a role in the pathogenesis of end organ hypertrophy and damage. 
Vlogo ima tudi pri patogenezi hipertrofije in okvare končnih organov.
Patients with such treatment should be monitored regularly and carefully. 
Tako zdravljene bolnike je treba redno in natančno kontrolirati.
The blood pressure was reduced from 166/90 to 145/80 mmHg in the candesartan group, and from 167/90 to 149/82 mmHg in the control group. 
Krvni tlak se je v skupini s kandesartanom znižal s 166/90 na 145/80 mmHg in v kontrolni skupini s 167/90 na 149/82 mmHg.
The CHMP considered that the benefit to risk ratio is positive also for patients in NYHA class IV and thus decided not to exclude these patients as recommended from the European Society of Cardiology (ESC). 
CHMP je menil, da je razmerje med koristmi in tveganji pozitivno tudi za bolnike iz razreda IV po NYHA, zato se je odločil, da skladno s priporočili Evropskega kardiološkega združenja (ESC) ne izključi omenjenih bolnikov.
• In some patients, such as those with liver problems, kidney problems or those who recently have lost body fluids, e.g., through vomiting or diarrhoea or by using water tablets, the doctor may prescribe a lower starting dose. 
• Nekaterim bolnikom, npr. tistim, ki imajo težave z jetri ali ledvicami, ali so pred kratkim izgubili tekočino (npr. zaradi bruhanja, driske ali uporabe tablet za odvajanje vode), lahko zdravnik predpiše manjši začetni odmerek.
In the elderly, the CHMP considered that no initial dose adjustment was needed in patients over 75 years of age. 
CHMP je menil, da pri bolnikih, starejših od 75 let, začetna prilagoditev odmerka ni potrebna.
If you are going to have an operation, tell your doctor or dentist that you are taking Atacand. 
Če imate predvideno operacijo, morate zdravniku ali zobozdravniku povedati, da jemljete zdravilo Atacand.
Based on available data, including results from the CHARM study programme (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) which included patients in NYHA functional class II to IV, the Committee noted there is no reason to exclude NYHA class IV patients. 
Na osnovi razpoložljivih podatkov, vključno z rezultati programa študij CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity - Kandesartan pri srčnem popuščanju: ocena zmanjšanja primerov umrljivosti in obolevnosti), v katerega so bili vključeni bolniki s funkcionalnimi razredi od II do IV po NYHA, je Odbor ugotovil, da ni razloga za izključitev bolnikov, ki spadajo v funkcijski razred IV po lestvici NYHA.
• if you have ever had a stroke. 
• če ste kdaj imeli možgansko kap.
• Heparin (a medicine for thinning the blood). 
• heparin (zdravilo proti strjevanju krvi).
Candesartan is an AIIRA, selective for AT1 receptors, with tight binding to and slow dissociation from the receptor. 
Kandesartan je AIIRA, selektiven za receptorje AT1; nanje se veže močno in se z njih sprošča počasi.
Like all medicines, Atacand can cause side effects, although not everybody gets them. 
Kot vsa zdravila ima lahko tudi zdravilo Atacand neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
• if you have severe liver disease or biliary obstruction (a problem with the drainage of the bile from the gall bladder). 
• če imate hudo bolezen jeter ali biliarno obstrukcijo (to je motnja odtekanja žolča iz žolčnika).
It is important to keep taking Atacand every day. 
Pomembno je, da zdravilo Atacand jemljete vsak dan.
• if you have heart, liver or kidney problems, or are on dialysis. 
• če imate težave s srcem, jetri ali ledvicami, ali če ste na dializi.
These events were more common in patients over 70 years of age, diabetics, or subjects who received other medicinal products which affect the renin-angiotensin-aldosterone system, in particular an ACE inhibitor and/or spironolactone. 
Ti dogodki so bili bolj pogosti pri bolnikih starejših od 70 let, diabetikih ali posameznikih, ki so prejeli druga zdravila, ki vplivajo na sistem renin-angiotenzin-aldosteron, še posebej zaviralec ACE in/ali spironolakton.
Non-Perforated foil, Perforated foil 
Neperforirana folija, perforirana folija
Evaluation of patients with heart failure should include periodic assessments of renal function, especially in elderly patients 75 years or older, and patients with impaired renal function. 
Ocena bolnikov s srčnim popuščanjem mora vključevati redne kontrole delovanja ledvic, zlasti pri starejših bolnikih, starih 75 let ali več, in bolnikih z okvarjenim delovanjem ledvic.
Candesartan is mainly eliminated unchanged via urine and bile and only to a minor extent eliminated by hepatic metabolism (CYP2C9). 
Kandesartan se v glavnem izloči nespremenjen v urinu in žolču in se le v majhni meri odstrani s presnovo v jetrih (CYP2C9).
Furthermore, candesartan induced hyperplasia/hypertrophy of the juxtaglomerular cells. 
Poleg tega je kandesartan povzročil hiperplazijo/hipertrofijo jukstaglomerularnih celic.
Your doctor may increase this dose to 16 mg once a day and further up to 32 mg once a day depending on blood pressure response. 
Zdravnik vam lahko ta odmerek poveča na 16 mg enkrat na dan in še dodatno do 32 mg enkrat na dan, odvisno od odziva krvnega tlaka.
LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTES OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 
SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVILA, POTI UPORABE, IMETNIKOV DOVOLJENJ ZA PROMET V DRŽAVAH ČLANICAH
There is no accumulation following multiple doses. 
Po več odmerkih ne pride do kopičenja.
However, it should be taken into account that occasionally dizziness or weariness may occur during treatment with Atacand. 
Vendar je treba upoštevati, da se med zdravljenjem z Atacandom občasno lahko pojavi omotica ali utrujenost.
• Changes in how your liver is working, including inflammation of the liver (hepatitis). 
• Spremembe delovanja jeter, vključno z vnetjem jeter (hepatitisom).
Consequently, uptitration of Atacand and concomitant therapy may be more frequently needed for blood pressure control in black patients than in non-black patients (see section 5.1). 
Zato utegne biti povečanje odmerka Atacanda in sočasno uporabljanih zdravil za obvladanje krvnega tlaka pogosteje potrebno pri bolnikih-črncih kot bolnikih-nečrncih (glejte poglavje 5.1).
For the purpose of harmonisation, the CHMP considered the national PI, answers provided by the marketing authorisation holder (MAH) and available scientific knowledge. 
Za namen usklajevanja je CHMP upošteval nacionalno odobrene informacije o zdravilu, odgovore, ki jih je posredoval imetnik dovoljenja za promet z zdravilom, in razpoložljivi znanstveni podatki.
• Potassium supplements or salt substitutes containing potassium (medicines that increase the amount of potassium in your blood). 
• dodatke kalija ali nadomestke soli, ki vsebujejo kalij (zdravila, ki povečujejo količino kalija v krvi).
The antihypertensive effect and tolerability of candesartan and losartan were compared in two randomised, double-blind studies in a total of 1,268 patients with mild to moderate hypertension. 
Antihipertenzivni učinek in prenašanje kandesartana in losartana so primerjali v dveh randomiziranih, dvojno slepih študijah pri skupno 1268 bolnikih z blago do zmerno hipertenzijo.
However, the blood pressure response and the incidence of adverse events are similar after a given dose of Atacand in young and elderly patients (see section 4.2). 
Toda odziv krvnega tlaka in incidenca neželenih učinkov sta po določenem odmerku Atacanda pri mladih in starejših bolnikih podobna (glejte poglavje 4.2).
In most of the MSs a dosage regimen up to a maximum of 32 mg dose was approved. 
V večini držav članic je odobren režim odmerjanja do največjega odmerka 32 mg.
Total plasma clearance of candesartan is about 0.37 ml/min/kg, with a renal clearance of about 0.19 ml/min/kg. 
Celotni plazemski očistek kandesartana je približno 0,37 ml/min/kg in njegov ledvični očistek je približno 0,19 ml/min/kg.
Candesartan cilexetil once daily provides effective and smooth blood pressure reduction over 24 hours, with little difference between maximum and trough effects during the dosing interval. 
Cileksetilkandesartanat enkrat na dan zagotavlja učinkovito in enakomerno 24-urno znižanje krvnega tlaka z majhno razliko med največjim in najmanjšim učinkom med odmernim intervalom.
• Other medicines to help lower your blood pressure, including beta-blockers, diazoxide and ACE 
• druga zdravila za zniževanje krvnega tlaka, vključno z zaviralci beta, diazoksidom in zaviralci
This is also confirmed in the recent meta-analysis by Law et al 2009, based on randomised trials. 
To potrjuje tudi nedavno objavljena metaanaliza randomiziranih preskušanj, ki so jo izvedli Law et al 2009.
Section 4.7 Effects on Ability to Drive and Use Machines 
Poglavje 4.7 Vpliv na sposobnost vožnje in upravljanja s stroji
• Treatment of essential hypertension in adults. 
• zdravljenje esencialne hipertenzije pri odraslih.
The table below presents adverse reactions from clinical trials and post-marketing experience. 
Spodnja preglednica navaja neželene učinke iz kliničnih preskušanj in postmarketinškega obdobja.
The overall incidence of adverse events showed no association with dose or age. 
Skupna incidenca neželenih učinkov ni bila povezana z odmerkom ali starostjo.
Atacand is contraindicated in patients with severe hepatic impairment and/or cholestasis (see sections 4.3 and 5.2). 
Atacand je kontraindiciran pri bolnikih s hudo okvaro jeter in/ali holestazo (glejte poglavji 4.3 in 5.2).
After administration of a single dose of candesartan cilexetil, onset of antihypertensive effect generally occurs within 2 hours. 
Po uporabi enkratnega odmerka cileksetilkandesartanata se antihipertenzivni učinek po navadi pojavi v 2 urah.
Do not take Atacand 
Ne jemljite zdravila Atacand
In individual case reports of overdose (of up to 672 mg candesartan cilexetil) patient recovery was uneventful. 
Opisani so posamezni primeri prevelikega odmerjanja (do 672 mg cileksetilkandesartanata); okrevanje bolnikov je v teh primerih potekalo brez zapletov.